Literature DB >> 17111085

Retroperitoneal lymph node dissection for high-risk stage I and stage IIA seminoma.

Zaza Mezvrishvili1, Laurent Managadze.   

Abstract

INTRODUCTION: The clinical results of radiotherapy in low-stage seminoma are excellent with negligible early morbidity. However, in a long-term follow-up various complications may occur. On the other hand, experience in nonseminomas shows that surgical morbidity has decreased markedly after invention of a nerve-sparing technique. These issues served as a rationale for us to perform the primary retroperitoneal lymph node dissection (RPLND) in seminoma patients.
MATERIALS AND METHODS: Fourteen pure seminoma patients (10 high-risk stage I and four with clinical stage IIA) underwent nerve-sparing RPLND from September, 1997 to December, 2002.
RESULTS: Pathological evaluation revealed lymph node involvement in three out of 10 clinical stage I and in all four stage IIA cases. The patients' acceptance of the surgery was good. Minor intra- and early postoperative complications were observed in two cases. Antegrade ejaculation was preserved in all patients. No retroperitoneal or distant recurrences have been observed. All patients were free of disease with the mean follow-up period of 56 months.
CONCLUSION: The excellent results and minimum morbidity of nerve-sparing RPLND together with the increased concerns on late complications of radiotherapy may turn the preference of surgery in low-stage seminoma into the subject of future discussion.

Entities:  

Mesh:

Year:  2006        PMID: 17111085     DOI: 10.1007/s11255-005-4793-x

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  30 in total

Review 1.  Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors: result of an update conference on evidence-based medicine (EBM).

Authors:  S Krege; R Souchon; H J Schmoll
Journal:  Eur Urol       Date:  2001-10       Impact factor: 20.096

2.  Prediction of long-term gonadal toxicity after standard treatment for testicular cancer.

Authors:  N Aass; S D Fosså; L Theodorsen; N Norman
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

3.  Relapses in early-stage testicular seminoma: radiation therapy versus retroperitoneal lymphadenectomy.

Authors:  N Warszawski; M Schmücking
Journal:  Scand J Urol Nephrol       Date:  1997-08

4.  Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation.

Authors:  M A Jewett; Y S Kong; S D Goldberg; J F Sturgeon; G M Thomas; R E Alison; M K Gospodarowicz
Journal:  J Urol       Date:  1988-06       Impact factor: 7.450

5.  Pilot studies of 2 and 1 course carboplatin as adjuvant for stage I seminoma: should it be tested in a randomized trial against radiotherapy?

Authors:  R T Oliver; P M Edmonds; J Y Ong; M J Ostrowski; A W Jackson; H Baille-Johnson; M V Williams; C R Wiltshire; T Mott; W R Pratt
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-04-30       Impact factor: 7.038

6.  Mortality after cure of testicular seminoma.

Authors:  Gunar K Zagars; Matthew T Ballo; Andrew K Lee; Sara S Strom
Journal:  J Clin Oncol       Date:  2004-01-15       Impact factor: 44.544

7.  Incidence of second primary cancer following testicular cancer.

Authors:  H Møller; A Mellemgaard; G K Jacobsen; D Pedersen; H H Storm
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

8.  Gastrointestinal morbidity of adjuvant radiotherapy in stage I malignant teratoma of the testis.

Authors:  C R Hamilton; A Horwich; J M Bliss; M J Peckham
Journal:  Radiother Oncol       Date:  1987-10       Impact factor: 6.280

9.  Complications of primary retroperitoneal lymph node dissection.

Authors:  J Baniel; R S Foster; R G Rowland; R Bihrle; J P Donohue
Journal:  J Urol       Date:  1994-08       Impact factor: 7.450

10.  Seminoma of the testis: long-term beneficial and deleterious results of radiation.

Authors:  G E Hanks; T Peters; J Owen
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

View more
  6 in total

Review 1.  Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer.

Authors:  Roy Mano; Renzo Di Natale; Joel Sheinfeld
Journal:  Urol Oncol       Date:  2018-11-13       Impact factor: 3.498

2.  First-line salvage treatment options for germ cell tumor patients failing stage-adapted primary treatment : A comprehensive review compiled by the German Testicular Cancer Study Group.

Authors:  David Pfister; Karin Oechsle; Stefanie Schmidt; Jonas Busch; Carsten Bokemeyer; Axel Heidenreich; Julia Heinzelbecker; Christian Ruf; Christian Winter; Friedemann Zengerling; Sabine Kliesch; Peter Albers; Christoph Oing
Journal:  World J Urol       Date:  2022-02-28       Impact factor: 4.226

Review 3.  Clinical stage II seminoma: management options.

Authors:  Muhannad Alsyouf; Siamak Daneshmand
Journal:  World J Urol       Date:  2021-10-16       Impact factor: 3.661

Review 4.  Management of Residual Mass in Germ Cell Tumors After Chemotherapy.

Authors:  Costantine Albany; Kenneth Kesler; Clint Cary
Journal:  Curr Oncol Rep       Date:  2019-01-21       Impact factor: 5.075

Review 5.  Outcomes and expanding indications for robotic retroperitoneal lymph node dissection for testicular cancer.

Authors:  Hailiu Yang; Daisy Obiora; Jeffrey J Tomaszewski
Journal:  Transl Androl Urol       Date:  2021-05

Review 6.  Retroperitoneal Lymph Node Dissection as Primary Treatment for Metastatic Seminoma.

Authors:  Brian Hu; Siamak Daneshmand
Journal:  Adv Urol       Date:  2018-02-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.